WASHINGTON, July 7, 2026
Vanda Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, the company’s investigational antisense oligonucleotide (ASO) therapy for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), an ultra-rare inherited neurological disorder affecting children. The designation, awarded by the FDA’s Office of Orphan Products Development and Office of Pediatric Therapeutics, represents an important regulatory milestone for Vanda’s precision medicine program targeting a devastating disease with no approved disease-modifying therapies. VCA-894A is a personalized antisense oligonucleotide therapy designed to target a unique IGHMBP2 genetic variant responsible for CMT2S, offering a highly tailored therapeutic approach for an exceptionally rare patient population. The FDA designation recognizes both the seriousness of the disease and the urgent need for innovative pediatric treatments while providing regulatory incentives that could accelerate clinical development and future commercialization. The company plans to continue working closely with the FDA to advance the investigational therapy through its development program.
Personalized Antisense Therapy Targets Ultra-Rare Genetic Neuropathy
Charcot-Marie-Tooth disease type 2S (CMT2S) is an extremely rare inherited neuromuscular disorder caused by mutations in the IGHMBP2 gene, leading to progressive degeneration of peripheral nerves, muscle weakness, sensory impairment, and gradual loss of motor function. The disease often begins during childhood and can progress to severe disability, including the loss of independent mobility. VCA-894A has been specifically engineered as a 2′-O-methoxyethyl (MOE) phosphorothioate antisense oligonucleotide that targets a cryptic splice-site mutation within IGHMBP2, correcting the underlying molecular defect responsible for the disease.
According to Vanda, the therapy is being developed for a patient diagnosed early in life with a unique genetic variant of CMT2S that has not been identified in any other individual, highlighting the growing potential of personalized genomic medicine in treating ultra-rare disorders. With an estimated global prevalence of fewer than one patient per million people, CMT2S represents one of the rarest inherited neurological diseases currently under investigation, making individualized therapeutic strategies increasingly important for affected patients and families.
FDA Designation Supports Development of Precision Rare Disease Therapies
Advertisement
The Rare Pediatric Disease Designation is intended to encourage the development of therapies for serious or life-threatening conditions that primarily affect children. The designation provides important regulatory incentives and may make VCA-894A eligible for a Rare Pediatric Disease Priority Review Voucher if the therapy ultimately receives FDA approval and satisfies all statutory requirements. Such incentives are designed to accelerate investment in rare disease drug development while expanding treatment options for pediatric patients with limited therapeutic alternatives. Vanda Pharmaceuticals stated that it will continue collaborating closely with the FDA as it advances the clinical development of VCA-894A, reinforcing the company’s broader commitment to developing innovative medicines for rare neurological diseases with significant unmet medical needs.
The investigational therapy also demonstrates the expanding role of antisense oligonucleotide technology, which has emerged as one of the most promising precision medicine platforms capable of targeting disease-causing genetic mutations at the RNA level. If future clinical studies confirm its safety and therapeutic potential, VCA-894A could represent a transformative personalized treatment for patients living with CMT2S while highlighting the growing impact of precision genomics and RNA-targeted therapeutics in rare pediatric disease research.
Source: Vanda Pharmaceuticals press release
